Objectives: Patient preference information (PPI) is gaining recognition among the
pharmaceutical industry, regulatory authorities, and health technology assessment (HTA)
bodies/payers for use in assessments and decision-making along the medical product
lifecycle (MPLC). This study aimed to identify factors and situations that influence the
value of patient preference studies (PPS) in decision-making along the MPLC according
to different stakeholders.
Methods: Semi-structured interviews (n = 143) were conducted with six different
stakeholder groups (physicians, academics, industry representa
